What are cannabinoids? Cannabinoids are chemical compounds that can be found within the Cannabis sativa species (and also in a handful of other flora). Cannabinoids are present naturally inside these types of plants, making up part of their biological structure. Cannabinoids found inside plants are technically called “phytocannabinoids”, but fall under the collective category of […]
Cannabinoids are chemical compounds that can be found within the Cannabis sativa species (and also in a handful of other flora). Cannabinoids are present naturally inside these types of plants, making up part of their biological structure. Cannabinoids found inside plants are technically called “phytocannabinoids”, but fall under the collective category of cannabinoids.
You could, to draw a picture, liken these cannabinoids to ingredients in a recipe—without them, you wouldn’t have the finished product; in this case, the hemp plant. And while cannabinoids are essential, they only form part of the recipe. We also need flavonoids and terpenes—but we will explain their function in a separate article.
Different cannabinoids in cannabis
Every cannabinoid has a slightly different purpose, but in total, there are believed to be over a hundred of them inside a single hemp plant. Part of the difficulty in understanding what each cannabinoid does stems from the fact that they don’t all exist at the same time or in similar concentrations. Many are only present while hemp is growing, while others need exposure to the atmosphere or sunlight before they can develop.
In general, mature hemp plants (that’s what we use to extract CBD) feature similar ratios of cannabinoids, including CBD, CBN, CBC, and many more. The letters are acronyms for their scientific names and help to differentiate between their chemical structure.
In hemp, CBD makes up the lion’s share of cannabinoids, while the others only feature in trace amounts. Using sophisticated machinery, it is possible to isolate specific cannabinoids and transform them into a consumable product—CBD oil, capsules, lotions, etc.
Having dozens of cannabinoids at hand is all well and good, but without a useful function, they are pretty pointless to us—that’s where the ECS steps in. Thanks to millions of years of evolution, each of us (including the household dog and cat) has an endocannabinoid system (ECS). This unique regulatory system is capable of interacting with cannabinoids, triggering a wide range of changes inside the body.
Cannabinoid receptors and the endocannabinoid system
The endocannabinoid system is a vast network that extends from the central nervous system to the major organs and nearly everywhere in between. Located at various points throughout the ECS are cannabinoid receptors. These receptors act as activation points, only reacting when they are stimulated or inhibited by cannabinoids.
When a cannabinoid is consumed (usually orally), it passes through our digestive system where it gets broken down by our liver, before being distributed around the body via the bloodstream. As it travels around the body, it aims for a receptor to interact with. However, it isn’t a complete free-for-all. Cannabinoid receptors work using a lock and key principle—this is why certain cannabinoids have effects that others don’t.
CBD, for example, will only interact with receptors that match its chemical structure. The same rules apply to all cannabinoids, as each one can only interact with specific receptors in specific locations throughout the body. Where that receptor is located determines which biological outcome is triggered.
There are dozens of cannabinoids, and they all do something different
We’ve covered a lot of ground, so it is worth recapping. CBD is one of dozens of cannabinoids found in the Cannabis sativa species. Cannabinoids are chemical compounds that have the unique ability to trigger changes within our body, thanks to the endocannabinoid system. The ECS has evolved over millions of years and exists throughout our entire body.
Its primary role is to maintain balance between all our biological systems. This is important because our body functions best when it is in a state of homeostasis (dynamic equilibrium). Finally, by consuming cannabinoids, we can encourage a range of subtle biological changes thanks to cannabinoid receptors linked to the ECS.
Although CBD is the cannabinoid we are most interested in, there are dozens of others—all with unique characteristics. We won’t go into detail in this article, but stay tuned for a deep dive into each one. If you’ve got a question about cannabinoids, you can trust us to have the answer.
Luka Dončić Joins Team BioSteel as Global Chief Hydration Officer
BioSteel today announced a historic long-term global partnership between the sports hydration company and all-star basketball player, Luka Dončić. Dončić has been appointed the title of Global Chief Hydration Officer. The partnership with BioSteel makes Dončić the latest addition to the brand’s impressive athlete roster including Patrick Mahomes. ‘I’m excited to work with BioSteel as Global […]
BioSteel today announced a historic long-term global partnership between the sports hydration company and all-star basketball player, Luka Dončić. Dončić has been appointed the title of Global Chief Hydration Officer. The partnership with BioSteel makes Dončić the latest addition to the brand’s impressive athlete roster including Patrick Mahomes.
‘I’m excited to work with BioSteel as Global Chief Hydration Officer because I am passionate about the importance of healthy hydration on and off the court,’ says Dončić. ‘This partnership is a great opportunity for me to teach today’s youth about the importance of clean, healthy hydration using BioSteel’s sports drinks.’
‘It’s important to us that our partnerships are authentic as we continue to grow our brand,’ says Michael Cammalleri, Co-Founder and Co-CEO. ‘As the Official Sports Drink of the Dallas Mavericks, Luka has been hydrating with BioSteel’s zero sugar sports drink for the entire season. We’re thrilled to announce a new partnership with Luka, who believes in our product, to amplify our story and accelerate our growth.’
Dončić joins a growing list of top tier athletes and ambassadors, which reflect the company’s roots of working with those who were consumers of the brand prior to being formally endorsed by BioSteel. As a member of Team BioSteel, Dončić will extend the brand’s footprint by reaching new health-conscious consumers and aspiring athletes.
Off the court, Dončić is passionate about his philanthropic endeavors, having recently donated to the Dallas Mayor’s Fund for Dallas winter storm relief. He is an avid gamer, is a fan of anime and can speak four languages fluently.
BioSteel is expanding in the U.S. market at a rapid pace, securing the country’s top grocery, mass, gas and convenience retailers, with direct distribution partners across the country to support this growth.
BioSteel’s environmentally-friendly sports drink with zero sugar can be purchased at BioSteel.com.
BioSteel is a North American operated sports hydration company that was built on the mandate of providing the safest, healthiest, and most effective line of nutritional products available. BioSteel’s line includes a range of nutritional products including sports drinks, proteins, and everyday essentials. BioSteel products are currently readily available across North America, and globally with select retail partners or direct to consumers online, through www.biosteel.com.
SOURCE BioSteel Sports Nutrition Inc.
For further information: Lindsey Soper, Communications Manager, BioSteel Sports Nutrition Inc., 647-537-9512, email@example.com
Canopy Growth Corp. published this content on 03 March 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 03 March 2021 14:38:50 UTC
(C) Copyright 2021 – Canopy Growth Corp.
Michael Berger is Managing Partner of StoneBridge Partners LLC. SBP continues to drive market awareness for leading firms in the cannabis industry throughout the U.S. and abroad.
Australis and 3 Rivers Biotech Enter into Tissue Culture Joint Venture
Australis Capital Inc. (CSE: AUSA) (OTC: AUSAF) today announced that the Company has entered into a binding terms sheet concerning a joint venture (JV) partnership with 3 Rivers Biotech Inc. (“3 Rivers”), a leading agricultural technology company specialised in commercial scale micropropagation, or plant tissue culture (PTC), for cannabis, hemp and traditional crops. The JV […]
Australis Capital Inc. (CSE: AUSA) (OTC: AUSAF) today announced that the Company has entered into a binding terms sheet concerning a joint venture (JV) partnership with 3 Rivers Biotech Inc. (“3 Rivers”), a leading agricultural technology company specialised in commercial scale micropropagation, or plant tissue culture (PTC), for cannabis, hemp and traditional crops.
Under the terms of the agreement, AUSA and 3 Rivers will own 15% and 85% of the JV, respectively. The intent of the JV is to jointly market the 3 Rivers’ offerings to growers. Through the JV, 3 Rivers will provide access to its IP and innovative services, products and solutions to AUSA sourced clients. These innovations include all current 3 Rivers offerings as well as access to future products such as PTC-based auto-flowering genetics, which provides a clonal hemp or cannabis plant that will flower independent of day length. This is a potential game changer for outdoor growers. AUSA will contribute sales and marketing capabilities and, through its deep industry network, the ability to generate new opportunities.
With over 1,000 cannabis companies, close to 600,000 acres planted with hemp in North America and Europe alone (representing approximately 1.1 billion plants) 1 , as well as 1.3 million acres 2 (~56.6 billion square feet) of global greenhouse vegetable area, the opportunity for 3 Rivers is very substantial (these numbers leave out greenhouse production of fruit). Through its innovative offerings and in particular its nearly peerless capabilities in cannabis and hemp, the company is exceptionally well positioned to deliver significant growth. The joint venture with AUSA will generate mutual benefits through increased access to marketing channels addressing the various markets both AUSA and 3 Rivers operate in.
Advantages of PTC
PTC entails growing a plant from a small number of cells, rather than from seeds or clones, under strictly controlled sterile conditions in a nutrient medium. PTC has numerous benefits with a significant positive impact on growers’ economic returns:
Increased facility ROI through true Generation Zero plantlets: PTC delivers disease-free starting material, increasing vigor (faster and healthier growth), and improved metabolite (cannabinoid or terpene) expression (greater product quality), increasing the economic return of a facility
Increased facility efficiencies: when adopting PTC, a cultivator no longer requires a mother room, thereby freeing up licensed space for flowering of commercially valuable crop, increasing a facility’s yield
Reduced risk of crop failure due to pathogen infestation
100% feminized stock avoids risk of rogue male plants, which can destroy an entire harvest
100% traceability of inputs, genetics, and biomass reduces compliance risks
Reduced chance of failing strict pesticide testing with clean, laboratory-produced plants
Ability to remove pathogens from existing cultivars: producing ‘clean’ plantlets, enhancing yield and quality of a new crop
Preservation of Rare or Endangered Species
Accelerated Propagation Once a Plant is in Tissue Culture
Improved Harvest Timing: reducing labor requirement s
The 3 Rivers Offering
3 Rivers Biotech is a plant biotechnology company specializing in commercial scale plant tissue culture for cannabis, hemp and traditional crops to provide premium pathogen-free, pesticide-free, vigorous plants to cultivators and late-stage nurseries across the United States and Internationally. The 3 Rivers products and services include:
Supply of micropropagation derived genetics, disease free Generation Zero plantlets for cannabis, hemp and other traditional crops (fruits, flowers, ornamentals, vegetables, etc.)
Ongoing PTC facility management and medium supply services
Clean-up of existing genetics: delivering a new generation of disease-free plantlets to growers
Storage of rare and valuable cultivars: genetics are the core property based on which growers generate revenues and establish brands. Genetics are therefore exceptionally valuable and safeguarding these is of great importance. PTC enables the indefinite preservation of these genetics.
Genetic fingerprinting: ensuring traceability and IP protection
Pathogen testing: screening for all predatory viruses, fungi, and oomycetes
3 Rivers has developed a production ready, prefabricated PTC lab, capable of producing up to 500,000 plantlets per year, the so-called InstaLab. These InstaLabs, which can be shipped anywhere in the world, greatly accelerate a company’s ability to implement PTC at commercial scale
3 Rivers also designs and develops PTC production as part of a retrofit of existing facilities, or integrated into the design of new facilities
Further innovations around Integrated Pest Management and the delivery of PTC-stable autoflowering varieties, on which the company has a provisional patent, are under development.
Dr. Duke Fu , Interim CEO of AUSA, stated, “We believe this new partnership will set the standard for science-based micropropagation, and be accretive to AUSA’s results. Being able to offer the propagation of cannabis through tissue culture at commercially viable scale is something that many companies and scientists have attempted, but that very few, if any, have managed to accomplish. This makes the 3 Rivers capabilities unique. The JV provides AUSA with access to an expanded portfolio of extremely valuable IP. We also believe this will strengthen our ability to execute on our capital-light strategy. For instance, being able to offer cultivation partners with PTC reduces the need for our cultivars to take up space in their facilities’ mother rooms, increasing the yield of any given facility. This JV further cements AUSA’s position as an authentic differentiator by offering a unique value add service that is exceptionally difficult to replicate.”
Robert Allen , CEO of 3 Rivers, added: “This partnership is transformative to 3 Rivers. By teaming up with AUSA, we believe we will be able to access new sales and marketing channels and rapidly expand our global footprint for PTC of cannabis, hemp and traditional crops. The JV accelerates our ability to bring our commercially focused innovations to market by gaining access to a deep industry network of industry leaders and operators, and help establish 3 Rivers as the leading company in this exciting and economically rewarding field.”
About 3 Rivers
3 Rivers is operational in Canada and Washington State , and is expanding into California and other jurisdictions. Its Washington cannabis operations, serving the local market, are at capacity and the company is in the process of expanding its in-state capacity. Its California operations anticipate internal, partner driven demand to grow to approximately 4-5 million plantlets in the coming years, with further growth coming through external sales.
Through its partnership with JRT Nurseries and its large-scale Mount Vernon tissue culture facility, 3 Rivers has the ability to scale and ship plants globally. This facility is one of the largest and most reputable plant tissue culture nurseries in North America , capable of producing over 12+ million plants annually. TheMount Vernon facility will be leveraged to service global markets for micro-propagated traditional crops, such as soft fruits and vegetables.
3 Rivers eliminates the risks and variables of commercial cultivation by providing its customers with stable genetics and vigorous, disease-free clones. The deeply experienced 3 Rivers team, with over 50 million plants supplied and counting, has been focused on perfecting plant propagation for decades. The unique combination of commercial scale PTC for cannabis, science-based R&D on applications with a rapid time to market and broad service offering have resulted in 3 Rivers rapidly expanding into becoming a world leader in its field.
AUSA is implementing a growth strategy towards establishing a highly competitive and profitable MSO in the U.S. and global cannabis markets. AUSA’s business and assets include investments in Cocoon, Body and Mind Inc., Quality Green, Folium Biosciences, and land assets in Washington and Michigan . AUSA is currently working towards the closing of a transaction whereby it will acquire 51% of ALPS, the world’s premier design, construction management, commissioning and post commissioning consultancy for horticultural crops, such as cannabis, fruits, vegetables, mushrooms and algae. If completed, the Company will also hold an option for the acquisition of the remaining 49% of ALPS. AUSA is also working towards completing the acquisition of Green Therapeutics LLC, an award-winning MSO with operations in Nevada , Missouri and Oklahoma . Through GT and ALPS, the Company believes it will be able to secure low-cost access to cannabis biomass to fuel the scale up of its award-winning brands across the U.S. and global cannabis markets.
The Company’s common shares trade on the CSE under the symbol “AUSA” and on the OTCQB under the symbol “AUSAF”.
For further information about AUSA, please contact:
This press release contains “forward-looking information” within the meaning of applicable securities legislation. All statements, other than statements of historical fact, included herein is forward-looking information. Generally, forward-looking information may be identified by the use of forward-looking terminology such as “plans”, “expects” or “does not expect”, “proposed”, “is expected”, “budgets”, “scheduled”, “estimates”, “forecasts”, “intends”, “anticipates” or “does not anticipate”, or “believes”, or variations of such words and phrases, or by the use of words or phrases which state that certain actions, events or results may, could, would, or might occur or be achieved. In particular, this press release contains forward-looking information in relation to: the the joint venture between AUSA and 3 Rivers closing and the ability to operate and execute; the timing and ability to close the proposed transactions with GT and ALPS; the anticipated development of the GT and ALPS businesses; the ability of the Company to execute on its strategy to establish a low capex model MSO; the impact of the changes to U.S. federal and state developments with respect to the cannabis industry and the opportunities this may present for the Company. This forward-looking information reflects the Company’s current beliefs and is based on information currently available to the Company and on assumptions the Company believes are reasonable. These assumptions include, but are not limited to: the ability of the Company to successfully satisfy the conditions to closing the ALPS and GT transactions; the ability of management of ALPS, GT and the Company to successfully execute on their respective business plans; legal changes relating to the cannabis industry proceeding as anticipated; and the Company’s continued response and ability to navigate the COVID-19 pandemic being consistent with, or better than, its ability and response to date.
Forward-looking information is subject to known and unknown risks, uncertainties and other factors that may cause the actual results, level of activity, performance or achievements of the Company to be materially different from those expressed or implied by such forward-looking information. Such risks and other factors may include, but are not limited to: general business, economic, competitive, political and social uncertainties; general capital market conditions and market prices for securities; the actual results of the Company’s future operations; competition; changes in legislation affecting the Company; the timing and availability of external financing on acceptable terms; lack of qualified, skilled labour or loss of key individuals; risks related to the COVID-19 pandemic.
A description of additional risk factors that may cause actual results to differ materially from forward-looking information can be found in the Company’s disclosure documents on the SEDAR website at www.sedar.com . Although the Company has attempted to identify important factors that could cause actual results to differ materially from those contained in forward-looking information, there may be other factors that cause results not to be as anticipated, estimated or intended. Accordingly, readers should not place undue reliance on forward-looking information. Readers are cautioned that the foregoing list of factors is not exhaustive. Readers are further cautioned not to place undue reliance on forward-looking information as there can be no assurance that the plans, intentions or expectations upon which they are placed will occur. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ materially from those anticipated.
Forward-looking information contained in this press release is expressly qualified by this cautionary statement. The forward-looking information contained in this press release represents the expectations of the Company as of the date of this press release and, accordingly, are subject to change after such date. However, the Company expressly disclaims any intention or obligation to update or revise any forward-looking information, whether as a result of new information, future events or otherwise, except as expressly required by applicable securities law.
The CSE has neither approved nor disapproved the contents of this news release. Neither the CSE nor its Regulation Services Provider (as that term is defined in the policies of the CSE) accept responsibility for the adequacy or accuracy of this release.
Constellation Brands Will Play A Huge Roll In The Success Of Canopy Growth’s U.S. CBD Beverage Rollout
The cannabis sector received a jolt of good news when Canopy Growth Corporation (WEED.TO) (CGC) announced a multi-faceted strategy to capitalize on the US cannabidiol (CBD) beverage market. Over the next year, we expect Canopy Growth to benefit from its strategic partnership with Constellation Brands (STZ), a multi-national beverage conglomerate that owns Corona. After Constellation […]
The cannabis sector received a jolt of good news when Canopy Growth Corporation (WEED.TO) (CGC) announced a multi-faceted strategy to capitalize on the US cannabidiol (CBD) beverage market.
Over the next year, we expect Canopy Growth to benefit from its strategic partnership with Constellation Brands (STZ), a multi-national beverage conglomerate that owns Corona. After Constellation announced its initial investment in Canopy Growth, we became very bullish on the long-term growth prospects of the Canadian cannabis company and are favorable on how the story has advanced since then.
Last night, Canopy Growth was featured on Jim Cramer’s Mad Money segment on CNBC. On the program, Canopy Growth CEO David Klein explained how it tests products in Canada before bringing them to the US market and has benefited from a test-and-learn process and expects Constellation to play a key role in how the product is distributed in the US.
This is not Canopy Growth’s first foray in the beverage market and in 2019, it acquired a majority stake of Biosteel, a sports nutrition products maker. CEO Klein expects Constellation to play an important role in how Biosteel branded products comes to market. We are favorable on the expertise that Constellation adds to the Canopy Growth team and expect the relationship to be a long-term leader in the global cannabis industry.
One of the reasons we are excited about the Quatreau CBD beverage line is based on its performance in Canada. Last year, Quatreau was the top-selling CBD beverage and benefited from a large spike in demand for cannabis-based products during the COVID pandemic.
The Quatreau beverage line that is sold in US will include 20 milligrams of hemp-based CBD that was grown in the US. We are favorable on the route that Canopy Growth is taking with sourcing premium hemp-based CBD and will be closely following this aspect of the story.
Although Canopy did not say when it plans to carry the product in US stores, we expect the brand to play an important role in its strategy to have a first mover advantage in the emerging US cannabis market and we will monitor how the leadership team from Canopy Growth and Constellation are able to execute on this.
During the last year, we have seen as pike in the number of Canadian cannabis prpdcuers that are focused on both the cannabis beverage and the US market. For instance, Aphria (APHA.TO) (APHA) and Tilray (TLRY) announced plans for a mega merger in late 2020. The development comes after Aphria acquired Sweetwater Brewing Company for approx. $300 million.
The combination of Aphria, Tilray and Sweetwater, creates a recipe to compete with Canopy Growth and this is an operator that our readers need to be aware of. We also expect Canopy Growth to face competition from HEXO Corp. (HEXO.TO) (HEXO) which is executing on the cannabis beverage vertical via a strategic partnership with Molson Coors Brewing (TAP).
If you are interested in learning about the companies that are positioned to capitalize on the cannabis beverage market, please send an email to firstname.lastname@example.org with the subject “Cannabis Beverage Leaders” to be added to our distribution list.
Michael Berger is Managing Partner of StoneBridge Partners LLC. SBP continues to drive market awareness for leading firms in the cannabis industry throughout the U.S. and abroad.